Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer.
Ann Oncol
; 20(11): 1794-802, 2009 Nov.
Article
en En
| MEDLINE
| ID: mdl-19556318
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias Ováricas
/
Antineoplásicos Alquilantes
/
Tetrahidroisoquinolinas
/
Dioxoles
/
Recurrencia Local de Neoplasia
Tipo de estudio:
Clinical_trials
/
Diagnostic_studies
Límite:
Adult
/
Aged
/
Female
/
Humans
/
Middle aged
Idioma:
En
Año:
2009
Tipo del documento:
Article